Plasma Protein Profiling to Discern Indolent from Advanced Systemic MastocytosisShow others and affiliations
2024 (English)In: Journal of Molecular Diagnostics, ISSN 1525-1578, E-ISSN 1943-7811, Vol. 26, no 9, p. 792-804Article in journal (Refereed) Published
Abstract [en]
Mastocytosis is a heterogeneous disorder characterized by abnormal mast cell accumulation, in which the clinical severity may be explained by distinct molecular mechanisms. This study aimed to explore plasma protein biomarkers associated with systemic mastocytosis subtypes, as well as the cellular origin of the identified proteins. Plasma samples from patients with mastocytosis, including cutaneous mastocytosis (CM), indolent systemic mastocytosis (ISM), and advanced systemic mastocytosis (AdvSM), and a reference group of patients with polycythemia vera, were analyzed by Proximity Extension Assay technology targeting 275 proteins. Furthermore, potential cellular origin was explored using an available single-cell RNA-sequencing data set generated from patients with ISM. The study cohort included 16 patients with CM, 92 patients with systemic mastocytosis (ISM, n = 80; AdvSM, n = 12), and 60 patients with polycythemia vera. A principal component analysis based on 275 plasma proteins revealed one cluster of patients with CM and ISM that was separated from patients with AdvSM. Up to 29 proteins were associated with distinct severe activity in patients with systemic mastocytosis (ISM versus AdvSM), including IL-1 receptor type 1 (IL-1RT1) and tumor necrosis factor ligand superfamily member 13B (TNFSF13B) (q < 0.01). Furthermore, single-cell RNA-sequencing analysis from ISM-derived bone marrow cells revealed that the mRNA for the identified proteins was not exclusive of mast cells. Distinct plasma protein profiles show potential to refine ISM and AdvSM diagnoses, possibly reflecting differences in pathogenic mechanisms and diverse clinical manifestations.
Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 26, no 9, p. 792-804
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-538815DOI: 10.1016/j.jmoldx.2024.05.010ISI: 001305705000001PubMedID: 38925457OAI: oai:DiVA.org:uu-538815DiVA, id: diva2:1902785
Funder
Swedish Cancer Society, 20 0929Swedish Research Council, 2020-01693Stiftelsen för Makarna Gottfrid och Karin Erikssons fond2024-10-022024-10-022024-10-02Bibliographically approved